Active Pharmaceutical Ingredient factory

Active Pharmaceutical Ingredient factory 1.Products Description What is Ticagrelor ? Ticagrelor 274693-27-5 is a brand-new class of antiplatelet aggregation medication created by AstraZeneca in the US. It is the first reversible oral P2Y12 adenosine diphosphate receptor antagonist ever created. The medication has a considerable inhibitory impact on platelet aggregation brought on by adenosine diphosphate (ADP), and it can reversibly act on the P2Y12 subtype of purinoceptor 2 receptors on vascular smooth muscle cells (VSMCs) without requiring metabolic activation. Additionally, it has an immediate effect after oral administration and can significantly lessen symptoms in people with acute coronary syndrome. In contrast to thienopyridine medications, Ticagrelor API is a reversible P2Y12 receptor inhibitor, making it especially useful for individuals who need anticoagulant therapy prior to surgery. AstraZeneca started developing ticagrelor in 1999. In 2009, the European Society of Cardiology (ESC) released the results of its Phase III trial, detailing its efficacy in treating patients with acute coronary syndrome (ACS). In November 2009, AstraZeneca submitted a new drug application for ticagrelor to the European Union and the U.S. Food and Drug Administration (FDA). In December 2010, ticagrelor received approval from the European Union for the prevention of atherosclerotic thrombotic events in adult patients with ACS. However, on December 17, 2010, the FDA decided to delay the approval of AstraZeneca's new antiplatelet drug ticagrelor and requested additional analysis of the PLATO study on platelet inhibition and patient prognosis. In January 2011, ticagrelor was officially marketed in all EU member countries under the brand name Brilique, with a dosage of 90mg per tablet and a package size of 60 tablets. On July 20, 2011, AstraZeneca announced that the FDA had approved ticagrelor for the reduction of cardiovascular death and heart attack in patients with ACS. Ticagrelor has been approved for marketing in 41 countries to date and has been included in the medical reimbursement scope in seven countries, such as the UK. Basic Information: Product name: Ticagrelor CAS:274693-27-5 MF:C23H28F2N6O4S MW:522.57 EINECS:619-540-9 MDL No.:MFCD09954148 Melting point:138-140 鈩?/p Boiling point:777.6卤70.0 鈩?Predicted) Density 1.67 storage temp. Keep in dark place,Inert atmosphere,Store in freezer, under -20掳C Stability: Stable Structural formula: Quality standard锛?/strong Test item Specification Result 銆?strongCharacters銆?/p AppearanceWhite or off-white solidOff-white solid SolubilityFreely soluble in MethanolConform 銆?strongIdentification銆?/p HPLCThe principal peak in the chromatogram obtained with the test solution is similar in retention time to the principal peak in the chromatogram obtained with reference solution.Conform 銆?strongTests銆?/p Moisture鈮?.50%0.22% Related substancesPurity鈮?9.00%99.7% Maximum single impurity鈮?.10%0.03%N.D. Residue on ignition鈮?.2%0.03% CONCLUSIONTHE QUALITY OF THE ABOVE-MENTIONED GOODS IS IN CONFORMITY WITH THE ENTERPRISE STANDARD. Function: Ticagrelor 274693-27-5 is an antiplatelet aggregation medication primarily used for the prevention and treatment of cardiovascular diseases. Its main functions include: Inhibition of platelet aggregation: it can bind to the P2Y12 receptors on platelets, limiting their activation by ADP and decreasing platelet aggregation and clot formation, hence preventing thrombosis. Cardioprotection: it has a direct cardioprotective effect in addition to its antiplatelet actions. Myocardial ischemia and injury are decreased, coronary artery blood flow is increased, and myocardial oxygen supply is improved. Treatment of acute coronary syndrome (ACS): it is frequently used in the treatment of acute coronary syndrome (ACS). It can be used to lower the risk of cardiovascular events in patients with stable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). In conclusion, ticagrelor can prevent thrombosis, lower the risk of cardiovascular events, and play a significant role in the treatment of ACS due to its suppression of platelet aggregation and direct cardioprotective effects. Please be aware that it is crucial to follow a healthcare professional's advice and thoroughly read the applicable drug instructions before taking any medication. Application: The following places are where ticagrelor is most commonly used: Treatment of Acute Coronary Syndrome (ACS): Stable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) are all included in the treatment of acute coronary syndrome (ACS). To lower the risk of myocardial infarction, stroke, or mortality in ACS patients, ticagrelor is administered as an antiplatelet treatment. Post-coronary artery stenting treatment: it is frequently used with aspirin for individuals who have had coronary artery stenting. This lessens the likelihood of cardiovascular events brought on by arterial re-narrowing and helps prevent thrombosis and restenosis. Long-term treatment of high-risk cardiovascular patients: Patients with high cardiovascular risk who need long-term care can benefit from ticagrelor. These patients may have diabetes or have numerous additional cardiovascular risk factors. It may reduce the chance of experiencing cardiovascular events including heart attacks and strokes. Please be aware that Ticagrelor should only be used under the supervision of a physician, and that side effects and any drug interactions should be carefully considered. It is best to speak with a healthcare professional for specialized guidance in any given case. Stability and storage: The storage conditions for Ticagrelor are as follows: Temperature: it should be stored at room temperature, avoiding exposure to excessively high or low temperatures. The recommended storage temperature range is typically between 15掳C and 30掳C (59掳F to 86掳F). Humidity: it should be stored in a dry environment, avoiding exposure to high humidity or damp conditions. Packaging: Keep the medication in its original packaging to protect it from moisture, light, and other harmful factors. Avoiding vibration: It is advisable to avoid excessive shaking or vibration that may affect the potency and stability of the medication. Please note that these storage conditions are general guidelines and may vary depending on the specific brand or manufacturer of Ticagrelor. Be sure to read and follow the specific storage instructions on the product label and consult your doctor or pharmacist before storing the medication. 2.Packing shipping Packing锛? 1~2kg 2-10kg 10-25kg Shipping锛?/strong 鈮?0kgBy express door to door Fedex, DHL,UPS,TNT,EMS ect. Fast and convenient 50kg~200kgBy air Fast and cheap 鈮?00kgBy sea Cheapest way Or as your requirement to choose the cheapest way or the fast. 3.Payment term 4.Why choose Xi'an Yihui? Customer feedback Xi'an Yihui company has the following advantages: Quality assurance: we use high-purity lead-free production technology. The product undergoes multiple strict production and quality testing procedures to ensure excellent product quality. Reasonable price: we have a relatively reasonable price compared to similar products. Excellent service: we have a professional technical team and after-sales service team, so that we can provide professional technical consultation and after-sales service to ensure customers get the best user experience. Unified brand image: we adopts a unified logo and design style on product packaging, making it easier for consumers to recognize the brand and enhancing the brand's influence. Xi 'an Yihui company's sales office, production equipment Xi鈥檃n Yihui Company has High level of research and development ability Xi'an Yihui Company's Advanced production equipment and technology Perfect after-sales service In summary, as a professional Ticagrelor 274693-27-5 manufacturer, we have advanced technology, scale advantage, the best quality, rich production experience, and excellent services. These advantages will make our Ticagrelor api stand out in the market competition and win more customer trust and support. if you need Ticagrelor, pls feel free to contact us any time. we will reply you asap. our contact information: E-mail: [email protected] Tel: 0086-29-89695240 WeChat or WhatsApp: 0086-17792415937Active Pharmaceutical Ingredient factory website:http://www.yihuipharm.com/active-pharmaceutical-ingredient/